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Abstract
Genital warts (GWs) and laryngeal papillomatosis (LP) are two usually benign pathologies related to infection with human papillomaviruses
(HPVs), mainly HPV6 and HPV11. The aim of this work was to describe the genetic diversity of HPV6 and HPV11 isolates found in GWs and
LPs, and to analyse the differential involvement of viral variants in either lesion. A total of 231 samples diagnosed as GWs (n = 198) or LP
(n = 33) and caused by HPV6 or HPV11 monoinfections were analysed. The phylogenetic relationships of the retrieved viral sequences
were explored. We have identiﬁed the long control region and the intergenic E2–L2 region as the two most variable regions in both HPV6
and HPV11 genomes. We have generated new HPV6 (n = 166) or HPV11 (n = 65) partial sequences from GWs and LPs lesions spanning
both regions and studied them in the context of all available sequences of both types (ﬁnal n = 412). Our results show a signiﬁcant (p <0.01)
differential presence of HPV6 variants among both pathologies, with HPV6 B variants being preferentially found in GW versus LP samples.
No differential involvement of HPV11 variants was observed. Our ﬁndings suggest that different HPV6 variants may either show differential
tropism or have different potential to induce lesions in different epithelia.
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Introduction
Papillomaviruses are small, non-enveloped viruses with a
circular double-stranded DNA genome of around 8000 bp
[1]. More than 250 complete papillomavirus genomes have
been described, infecting human and non-human hosts (http://
pave.niaid.nih.gov/#home). Human papillomaviruses (HPVs)
are the causative agents of cancer of the cervix, and are also
involved in cancers of the penis, anus, vagina, vulva, and head
and neck, as well as in other benign, wart-like lesions [2]. Based
on this association to cervical cancer, HPVs have been
epidemiologically stratiﬁed into three risk groups: carcino-
genic, probably and possibly carcinogenic, and not carcinogenic
to humans [3]. Alphapapillomaviruses HPV6 and HPV11 belong
to the non-carcinogenic group, being the most common non-
oncogenic HPVs found in cervical specimens in the general
population [4].
HPV6 and HPV11 are the causative agents in some
conspicuous lesions, namely anogenital warts (GWs) and
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laryngeal papillomatosis (LP). GWs are benign tumours of the
epithelium caused by papillomavirus infection, mainly with
HPV6 and HPV11 (85% of the cases) [5]. Co-infections by
oncogenic and non-oncogenic types are commonly detected in
a high proportion of anogenital warts (45%), which have been
proposed as a partial explanation of the increased risk of
cervical intraepithelial neoplasia and invasive cervical carci-
noma in women with GWs [6]. GWs are closely associated
with sexual behaviour, with number of sexual partners being
the main risk factor [7]. The highest incidence rate for GWs in
women is at 20–24 years, which correlates well with the peak
of papillomavirus infection in the female genital tract [4]. In
men, the incidence peak occurs at 20–29 years of age [2].
Laryngeal papillomatosis, or recurrent respiratory papillo-
matosis, is a neoplastic disease of the airways mainly caused by
HPV6 and HPV11, although HPV16 has also been identiﬁed in a
few cases [8]. It represents the most common benign tumour
of the larynx in infants and children [9]. Some studies have
identiﬁed infection with HPV11 as being associated with more
aggressive disease and higher recurrence of lesions [8,10], and
malignant transformation of lesions has been described in
approximately 5% of cases [11]. The clinical complications of
this pathology include dysphonia, dyspnoea and, in serious
cases, complete obstruction of the airways [12].
Papillomavirus variants are deﬁned as viral sequences
sharing >98% identity in the nucleotide sequence in the L1
gene [13]. Based on this criterion, HPV6 and HPV11 variant
lineages have been described [14]. Several studies have
addressed the genetic diversity of HPV6 and HPV11 [15–17],
and some of them have aimed to establish a link between
genetic variation and differential outcome of the infection
[8,18].
The aim of this study was to analyse ﬁrst the genetic
diversity of HPV6 and HPV11 sequences retrieved from two
different but related pathologies, namely GWs and LP. Further,
the phylogenetic relationship of all HPV6 and HPV11




Samples analysed in this project originate from two different
formalin-ﬁxed parafﬁn-embedded (FFPE) sample repositories.
GWs were obtained from the Surgical Genital Wart Biobank
established in 1995 at the Sexual Health Clinic at Royal Perth
Hospital, Perth, Australia. These samples include FFPE surgery
specimens excised from patients who required surgical
resection of anal and/or perianal GWs [19]. One hundred
and forty-three HPV6 and sixty-four HPV11 single infected
samples from the ﬁrst surgical event of each patient were
included.
Laryngeal papillomatosis samples originated from a multi-
centre study of cases diagnosed between 1985 and 2009, in the
cities of Cali and Medellin, Colombia [10]. Forty-one HPV6 and
eleven HPV11 single-infected samples, each from a different
patient, were included. Detailed information about the samples
included is shown in the Supplementary material, Table S1.
Presence of HPV DNA in the samples was assessed by using
the SPF10-DEiA-LiPA protocol (version 1; Laboratory Biomed-
ical Products, Rijswijk, the Netherlands). The SPF10 system
targets a 65-base pair region of L1 gene of a broad spectrum of
Alphapapillomaviruses. HPV-positive samples were identiﬁed
and genotyped by amplicon hybridization (DEiA) and reverse
hybridization line probe assay, LiPA25. The detected viruses
were HPV6, 11, 16, 18, 31, 33, 34, 35, 39, 40, 42, 43, 44, 45, 51,
52, 53, 54, 58, 59, 56, 66, 68, 70 and 74.
Selection of the most informative genomic regions
Fragmentation of genetic material in the FFPE samples
prevented us from obtaining full-genome sequences. To select
the most informative regions for the study, the variability of
different regions of the viral genomes was assessed.
HPV6 and HPV11 complete genome unique sequences were
obtained via GenBank. The different open reading frames
(ORFs: E6, E7, E1, E2, L1 and L2), the long control region (LCR),
and the intergenic E2–L2 region (IntE2L2) were extracted and
aligned. This intergenic region spans the E5a and E5b ORFs of
HPV6 and HPV11 [20]. All sequences were aligned at amino
acid level (except the non-coding LCR), back-translated and
concatenated to obtain full-genome reference alignments. For
each of the alignments, phylogenetic relationships were inferred
under a maximum likelihood framework using RAxML v7.2.8
(http://www.exelixis-lab.org/) [21], using the GTR+Γ4 model,
and the number of required bootstrap cycles was determined
with the –autoMRE command [22]. The well-resolved phyloge-
netic trees obtained were further employed to compute tree-
guided, model-based pairwise genetic distances between taxons
(f x command in RAxML).
PCR and sequencing
DNA was extracted by incubation of the material with 250 lL
of proteinase K buffer (10 mg/mL proteinase K in 50 mM
Tris–HCl, pH 8.0) overnight at 56°C. The samples were later
incubated at 95°C for 8 min to inactivate proteinase K and
were stored at 20°C until use.
Based on the pairwise distance results, the LCR and the
IntE2L2 were chosen as ampliﬁcation targets. Different
type-speciﬁc PCR systems were designed for the ampliﬁcation
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of the samples. One primer set per region per genome was
initially designed. For HPV6 samples not ampliﬁable by the
primer set because of amplicon length, targeted regions were
obtained by ampliﬁcation of overlapping fragments. Primer
sequences and ampliﬁed regions are shown in the Supplemen-
tary material, Table S2.
PCR products were sequenced at the Genoscreen facilities
(Lille, France) in both strands.
Phylogenetic analyses
We have applied an Evolutionary Placement Algorithm (EPA)
[23] to the inference of the phylogenetic relationships of the
short fragments generated, in the context of the whole HPV6
or HPV11 variability. This methodology had been successfully
applied for the analyses of short papillomavirus DNA
sequences [24]. The reference tree described above, inferred
using the genomic information of all full-length HPV6 or
HPV11 variants, was used as scaffold.
The ﬁnal set of reference sequences contained: for HPV6,
38 sequences, 8047 nucleotides and 172 alignment patterns;
for HPV11, 26 sequences, 7878 nucleotides and 77 alignment
patterns. These sets included sequences obtained from
different pathologies (GWs, LP, cervical and lung samples) in
different regions (Slovenia, Sweden and Thailand). Detailed
information on the sequences is shown in Table S1.
Sequences obtained from our samples, and those partial
sequences retrieved from GenBank were included and aligned
with the reference sequences. Genome alignments were
chopped to the length of the larger partial sequence in the
alignments. Final alignment included 253 sequences, 1432
nucleotides and 343 alignments patterns for HPV6; 159
sequences, 1452 nucleotides and 157 alignment patterns for
HPV11. The EPA algorithm was performed as implemented in
RAXML v7.2.6, using the GTR+Γ4 model.
The results of the variants distribution in different pathol-
ogies were compared by means of the Pearson’s chi-squared
test for count data as implemented in R.
Results
LCR and IntE2L2 are the most informative regions
We studied the distribution of pairwise genetic distances for
the different genomic regions among full-length genomes of
HPV6 and HPV11. The most variable regions in both HPVs
were IntE2L2, E2 and LCR; and E6 for HPV11 only (see
Supplementary material, Table S3). The accumulated frequen-
cies of the pairwise distances for each ORF and the values of
the 95th centile are depicted in Fig. 1. The study of E6 was
discarded because we chose to use the same regions for the
study of both HPV6 and HPV11, and the E6 gene was not
informative for HPV6 variability [25]. E2 was discarded
because we aimed to maximize the number of sequences
from other studies for our combined analyses, and the only E2
sequences available in the GenBank were those of the
full-length genomes. Hence, the most informative regions,
IntE2L2 and LCR, were chosen for further analyses.
HPV6 variants analysis
One hundred and sixty-eight GW and LP samples were
successfully ampliﬁed and sequenced. All newly generated
sequences ﬁtted into the previously described clades [14]
(a)
(b)
FIG. 1. (a) Human papillomavirus strain 6 (HPV6) pairwise distances
calculated for full-genome, LCR and IntE2L2 of reference sequences;
(b) HPV11 pairwise distances calculated for full-genome, LCR and
IntE2L2 of reference sequences. Note that both plots are represented
at the same scale. Dashed lines represent the distances pairwise values
for 95th centile.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O406–O413
O408 Clinical Microbiology and Infection, Volume 20 Number 6, June 2014 CMI
(Fig. 2). Likelihood weights for the ascription of each individual
sequence to each clade/subclade are shown in the Supplemen-
tary material, Table S4. Detailed information on the distribu-
tion of the sequences in the different clades is presented in
Table 1.
Ten partial sequences were excluded for the analyses of the
global dataset because no information regarding anatomical
site of the lesion was available. Finally, the analysis conducted
with 243 sequences showed that 32 out of 85 LP samples
belonged to clade A (37.7%), and the remaining sequences
belonged to clade B (n = 53, 62.3%) [B1: 30 (35.3%); B2: 6
(7.1%); B3: 17 (20.0%)]. Among all HPV sequences identiﬁed in
GWs, ten (6.3%) belonged to clade A, and 148 (93.7%) to clade
B [B1: 108 (68.4%); B2: 34 (21.5%); B3: 6 (3.8%)] (Table 1).
Fig. 2(b) displays the generated tree, including the whole set of
sequences.
The differential presence of the different variants in GWs and
in LP was further analysed. In both GWs and LP HPV6 B variants
were the most common, 93.6% and 62.4%, respectively.
However, a signiﬁcant difference (chi-squared test; p <0.01)
was observed between the distribution of variants between the
two types of lesions. While in GWs almost two-thirds of
sequences belonged to subclade B1, in LP we found an increased
contribution of A (38%) and B3 variants (20%).
TABLE 1. Distribution of the analysed human papillomavirus
6 (HPV6) sequences into phylogenic clades
Clade
GWs LP
No. samples % No. samples %
A 10 (7) 6.33 32 (14) 37.65
B 148 (135) 93.67 53 (10) 62.35
B1 108 (97) 68.35 30 (–) 35.30
B2 34 (33) 21.52 6 (1) 7.05
B3 6 (5) 3.80 17 (9) 20.00
Total 158 (142) 100.00 85 (24) 100.00
The comparison of the distribution of HPV6 variants among both pathologies,
genital warts (GWs) and laryngeal papillomatosis (LP), shows a statistically
signiﬁcant difference (chi-squared test p <0.01).


















FIG. 2. (a) Midpoint rooted best-known maximum likelihood (ML) phylogenetic tree of human papillomavirus strain 6 (HPV6) isolates using 38
unique full-length genome sequences retrieved from GenBank. HPV6 variants are classiﬁed into two clades, A and B. Only bootstrap values over 70
supporting each branch of the generated tree are represented; (b) projection of the LCR/IntE2L2 HPV6 sequences analysed in this study onto the
scaffold of the best-known full-length ML tree using the Evolutionary Placement Algorithm approach. Some branches have been collapsed for better
presentation, the collapsed branches include: (1) 6 GWs/20 LPs/2 Cervix; (2) 32GWs; (3) 66 GWs/45 LP/2 Cervix; (4) 23 GWs/4 LPs; (5) 4 GWs/12
LP. Sequences newly generated in this study are shown in red. An uncollapsed version of the tree is available from the authors under request.
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HPV11 variants analysis
Sixty-ﬁve samples were successfully ampliﬁed and sequenced.
All HPV11 sequences ﬁtted into the previously described clades
(Fig. 3). Likelihood weights for the assignment of each individual
sequence to each clade/subclade are shown in Table S4.
Detailed information on the distribution of the sequences in
the different clades is presented in Table 2.
Eleven partial HPV11 sequences retrieved from GenBank
were not included in the ﬁnal analyses because of unknown
origin of the material. Fig. 3(b) shows the generated tree,
including the complete set of sequences. In both GWs and LP
the vast majority of sequences belonged to the HPV11 A2
clade, with no difference between variant distributions
depending on the different types of lesion (chi-squared test
p 0.493).
Discussion
Both GWs and LP are benign proliferative lesions caused
mainly by HPV6 and HPV11 [2]. Both types of lesions present
similar clinical features, such as high recurrence and need of
long-term treatments, and have been linked to the develop-
ment, in a small proportion of patients, of malignant neoplasms
[11]. Previous studies have addressed differential HPV6 and
HPV11 genotype distributions in GWs and LP, but mainly at a
national/regional level [18,26,27]. Here we provide the ﬁrst
study analysing HPV6 and HPV11 variant distribution in two
different pathologies, with a large number of samples, GWs









FIG. 3. (a) Midpoint rooted best known maximum likelihood (ML) phylogenetic tree of human papillomavirus strain 11 (HPV11) variants using 26
unique full-length genome sequences retrieved from GenBank. The HPV11 variants are classiﬁed into one clade (A) and two sub-clades (A1, A2).
Only bootstrap values over 70 supporting each branch of the generated tree are represented; (b) projection of the LCR/IntE2L2 HPV11 sequences
analysed in this study onto the scaffold of the best-known full-length ML tree. Some branches have been collapsed for better presentation, the
collapsed branches include: (1) 31 GWs/6 LPs; (2) 26 GWs/4 LP/2 Cervix; (3) 18 GWs/1 LPs. Sequences newly generated in this study are shown in
red. An uncollapsed version of the tree is available from the authors under request.
TABLE 2. Distribution of the analysed human papillomavirus
11 (HPV11) sequences into phylogenic clades
Clade
GWs LP
No. samples % No. samples %
A1 6 (2) 5.50 3 (1) 7.5
A2 103 (54) 94.50 37 (8) 93.5
Total 109 (56) 100.00 40 (9) 100.00
The comparison of the distribution of HPV11 variants among both pathologies,
genital warts (GWs) and laryngeal papillomatosis (LP), shows no statistically
signiﬁcant difference (chi-squared test p 0.493).
Numbers in brackets correspond to new sequences generated from the sample
collections described.
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sequences in the GenBank generates a ﬁnal dataset of 253
samples for HPV6, and 159 samples for HVP11 sequences,
encompassing ten countries (Australia, China, Colombia,
Germany, Hungary, Slovenia, South Africa, Sweden, Thailand,
USA) and ﬁve continents.
We have identiﬁed the most suitable genomic regions for
assessing intratype genetic diversity, which for HPV6 and
HPV11 are the LCR and the IntE2L2 regions (Table S3). Similar
data on the heterogeneous rate of variation throughout the
papillomavirus genomes had been previously described.
Among coding regions, the E5 genes are the fastest evolving
ORFs, and E1 and L1 are the more slowly evolving genes
[20,28]. The LCR itself, devoid of the selective pressures for
protein encoding, accumulates changes more than twice as fast
as the L1 or the E1 genes [28]. Our results conﬁrm therefore
that the general trend of variation accumulation is conserved
also at shallower levels within Papillomaviridae.
HPV6 and HPV11 are close relatives, and belong together in
Alphapapillomaviruses, species 10. Genetic diversity is about
four times greater among HPV6 isolates than among HPV11
isolates, as concluded after the analyses of all available
full-length genomes for both viruses (Wilcoxon’s test,
p <0.01) (Fig. 1). These diversity values ﬁt well the described
taxonomic deﬁnition: for HPV6 variants based on nucleotide
similarities in the L1 gene, intravariant differences are around
0.7% and intervariant differences are around 1.5%; for HPV11,
no different variants are described and nucleotide differences
are below 0.5% [14]. The EPA approach [23] allowed us to
assign all partial sequences into the different clades deﬁned
using the full-length genome sequences (Fig. 2, Fig. 3). The
most important ﬁnding of our study is that HPV6 A and B
variants are not equally distributed in GWs and LP (p <0.01).
Speciﬁcally, HPV6 B variant isolates are preferentially found in
GWs compared with LP. Furthermore, the contribution of
subclades within HPV6 B variants is also different in GWs and
in LP (p <0.01). No distribution difference could be observed
in our data for HPV11 variants. It could be argued that the
observed differences arise from a geographical bias for the
origin of the samples analysed. However, previous research did
not identify geographical origin as an important component of
viral diversity for HPV6 and HPV11. Heinzel and co-workers
communicated a global study of these two HPVs [15], including
19 samples containing HPV6 and ten samples containing
HPV11. More recently, de Matos et al. presented data on the
phylogenetic relations of HPV6 variants using 117 sequences
from South America, Europe and South Africa [29], suggesting
no evidence of a geographical distribution of HPV variants in
these lesions. Further, more local studies have reported that
the whole repertoire of HPV6 variants can be found in isolates
originating from a single country [25].
It was not the aim of this study to assign a differential risk
for certain variants, as this is not a case–control study. The low
prevalence of both studied HPVs in a healthy population
worldwide (0.5% for HPV6; 0.2% for HPV11) [4] makes it
difﬁcult to obtain a sample size with enough statistical power
for a meaningful comparative study.
In summary, in this study we demonstrate the differential
presence of papillomavirus variants in different pathologies,
with variants B1 of HPV6 being more prevalent in GWs than in
LP. The current state of knowledge therefore supports our
ﬁnding of a preferential involvement of HPV6 B1 variants in
GWs, which may reﬂect a biological difference in the interplay
between viruses and the different mucosal epithelia. Such
differences may arise from either a preferential tropism or a
differential viral ﬁtness and potential to induce lesions between
anogenital and laryngeal mucosa. Similar scenarios have been
proposed for HPV16 variants differentially enriched in vulvar
cancer compared with cervical cancer [30]. Further research
on the prevalence of the different variants within HPV6 in
healthy tissue from both locations will be necessary to solve
this question.
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